Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 2.1% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 10.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patienttherapytumoriicombination
  Phrases that lowered it: evaluate theto evaluatedrugand safetyamlodipine
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 76.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 119216 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Blinding: double (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 48 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension NCT02944734 · started 2014 · scored riskier than 10% of active trials completed
• Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension NCT05920005 · started 2023 · scored riskier than 33% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy NCT02368652 · started 2014 · scored riskier than 12% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy NCT02368665 · started 2014 · scored riskier than 12% of active trials completed
• Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy NCT06236061 · started 2024 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.